Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01482715 · ClinicalTrials.gov registry record · Phase 1
A Study of Oral Rucaparib in Patients With a Solid Tumor (Phase I) or With gBRCA Mutation Ovarian Cancer (Phase II)
A Phase 1 study, sponsored by pharmaand.
- Completed
- Registry status
- Phase 1
- Development phase
- 136
- Enrollment target
NCT01482715 is a Phase 1 study that has completed, run by pharmaand. The registered enrollment target is 136 participants.
The verdict
NCT01482715, a Phase 1 study, has completed, sponsored by pharmaand.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 136 participants
- Enrollment target
Study Summary
Part 1 (Completed Enrollment) - The purpose of the first part of the study was to evaluate the safety of different doses and dosing regimens of oral rucaparib administered daily to patients with solid tumors. Part 2A (Completed Enrollment) and Part 2B (Completed Enrollment) - The purpose of the second part of the study is to determine the safety and clinical activity of the RP2D of oral rucaparib administered daily to patients with a known deleterious BRCA mutation (germline or somatic). Part 3 (Completed Enrollment) - The purpose of the third part of the study is to further evaluate PK of higher dose strength tablets at the RP2D in patients with any advanced solid tumor, inclusive of lymphoma, with evidence of a BRCA mutation (germline or somatic).
Interventions
- DRUG Rucaparib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 136 participants |
| Start Date | 2011-11 |
| Est. Completion | 2019-05 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01482715
The ClinicalTrials.gov registry entry for NCT01482715 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 136 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is pharmaand, which has 15 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Rucaparib is the first listed.
NCT01482715 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01482715 about?
NCT01482715 is a clinical study titled "A Study of Oral Rucaparib in Patients With a Solid Tumor (Phase I) or With gBRCA Mutation Ovarian Cancer (Phase II)". Part 1 (Completed Enrollment) - The purpose of the first part of the study was to evaluate the safety of different doses and dosing regimens of oral rucaparib administered daily to patients with solid tumors. Part 2A (Completed Enrollment) and Part 2B (Completed Enrollment) - The purpose of the sec...
What is the current status of trial NCT01482715?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 136 participants. The study started on 2011-11. Estimated completion is 2019-05.
What interventions are being tested in trial NCT01482715?
The interventions under investigation include: Rucaparib (DRUG).
Who is sponsoring clinical trial NCT01482715?
This trial is sponsored by pharmaand, which has 15 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.